What is Sigmoid Pharma?
Founded in 2003, Sigmoid Pharma operates as a privately-held entity within the competitive biotech sector. The company's focus on developing innovative pharmaceutical solutions positions it as a key player in its market. Its longevity and continued pursuit of strategic investments suggest a robust pipeline and a commitment to advancing healthcare.
How much funding has Sigmoid Pharma raised?
Sigmoid Pharma has raised a total of $6.3M across 1 funding round:
Private Equity
$6.3M
Private Equity (2014): $6.3M with participation from Pendopharm
Key Investors in Sigmoid Pharma
Pendopharm
Pendopharm is a Canadian specialty pharmaceutical company focused on developing, in-licensing, and commercializing innovative medicines, particularly in gastroenterology, sports medicine & orthopedics, neurology, and cardiology. Their commitment to innovation aims to address unmet medical needs and improve patient health outcomes.
What's next for Sigmoid Pharma?
The substantial enterprise-level funding and recent strategic investment indicate Sigmoid Pharma is poised for significant expansion and further research and development initiatives. This capital infusion is likely to accelerate the company's growth trajectory, potentially enabling new drug discovery, clinical trials, or market penetration strategies. The company's strategic positioning suggests a focus on scaling operations and solidifying its market share in the pharmaceutical industry.
See full Sigmoid Pharma company page
